Implementation of an Immunoassay Based on the MVA-T7pol-Expression System for Rapid Identification of Immunogenic SARS-CoV-2 Antigens: A Proof-of-Concept Study DOI Open Access

Satendra Kumar,

Liangliang Nan, Georgia Kalodimou

и другие.

International Journal of Molecular Sciences, Год журнала: 2024, Номер 25(20), С. 10898 - 10898

Опубликована: Окт. 10, 2024

The emergence of hitherto unknown viral pathogens presents a great challenge for researchers to develop effective therapeutics and vaccines within short time avoid an uncontrolled global spread, as seen during the coronavirus disease 2019 (COVID-19) pandemic. Therefore, rapid simple methods identify immunogenic antigens potential therapeutical targets are urgently needed better pandemic preparedness. To address this problem, we chose well-characterized Modified Vaccinia virus Ankara (MVA)-T7pol expression system establish workflow immunogens when new pathogen emerges, generate candidate vaccines, test their immunogenicity in animal model. By using system, detected severe acute respiratory syndrome (SARS) 2 (SARS-CoV-2) nucleoprotein (N)-, spike (S)-specific antibodies COVID-19 patient sera, which is line with current literature our observations from previous studies. Furthermore, directed against SARS-CoV-2-membrane (M) -ORF3a proteins sera aimed recombinant MVA expressing either M or ORF3a protein. When testing prime-boost immunization regimen humanized HLA-A2.1-/HLA-DR1-transgenic H-2 class I-/class II-knockout mice, were able demonstrate M- ORF3a-specific cellular humoral immune responses. Hence, established MVA-T7pol represents efficient tool provides basis future development vaccines.

Язык: Английский

The Key to Increase Immunogenicity of Next-Generation COVID-19 Vaccines Lies in the Inclusion of the SARS-CoV-2 Nucleocapsid Protein DOI Creative Commons
Noe Juvenal Mendoza-Ramírez, Julio García‐Cordero, Gaurav Shrivastava

и другие.

Journal of Immunology Research, Год журнала: 2024, Номер 2024, С. 1 - 18

Опубликована: Май 29, 2024

Vaccination is one of the most effective prophylactic public health interventions for prevention infectious diseases such as coronavirus disease (COVID-19). Considering ongoing need new COVID-19 vaccines, it crucial to modify our approach and incorporate more conserved regions severe acute respiratory syndrome 2 (SARS-CoV-2) effectively address emerging viral variants. The nucleocapsid protein a structural SARS-CoV-2 that involved in replication immune responses. Furthermore, this offers significant advantages owing minimal accumulation mutations over time inclusion key T-cell epitopes critical immunity. A novel strategy may be suitable generation vaccines against use combination antigens, including spike proteins, elicit robust humoral potent cellular responses, along with long-lasting strategic multiple antigens aims enhance vaccine efficacy broaden protection viruses, their response from other long-lasting, can persist up 11 years post-infection. Thus, incorporation nucleocapsids (N) into design adds an important dimension vaccination efforts holds promise bolstering ability combat effectively. In review, we summarize preclinical studies evaluated antigen. This study discusses alone its or proteins SARS-CoV-2.

Язык: Английский

Процитировано

6
Single dose VSV-based vaccine protects mice against lethal heterologous Crimean-Congo hemorrhagic fever virus challenge DOI Creative Commons
Thomas Tipih,

Shanna Leventhal,

Kimberly Meade‐White

и другие.

npj Vaccines, Год журнала: 2025, Номер 10(1)

Опубликована: Май 30, 2025

Язык: Английский

Процитировано

0
Implementation of an Immunoassay Based on the MVA-T7pol-Expression System for Rapid Identification of Immunogenic SARS-CoV-2 Antigens: A Proof-of-Concept Study DOI Open Access

Satendra Kumar,

Liangliang Nan, Georgia Kalodimou

и другие.

International Journal of Molecular Sciences, Год журнала: 2024, Номер 25(20), С. 10898 - 10898

Опубликована: Окт. 10, 2024

The emergence of hitherto unknown viral pathogens presents a great challenge for researchers to develop effective therapeutics and vaccines within short time avoid an uncontrolled global spread, as seen during the coronavirus disease 2019 (COVID-19) pandemic. Therefore, rapid simple methods identify immunogenic antigens potential therapeutical targets are urgently needed better pandemic preparedness. To address this problem, we chose well-characterized Modified Vaccinia virus Ankara (MVA)-T7pol expression system establish workflow immunogens when new pathogen emerges, generate candidate vaccines, test their immunogenicity in animal model. By using system, detected severe acute respiratory syndrome (SARS) 2 (SARS-CoV-2) nucleoprotein (N)-, spike (S)-specific antibodies COVID-19 patient sera, which is line with current literature our observations from previous studies. Furthermore, directed against SARS-CoV-2-membrane (M) -ORF3a proteins sera aimed recombinant MVA expressing either M or ORF3a protein. When testing prime-boost immunization regimen humanized HLA-A2.1-/HLA-DR1-transgenic H-2 class I-/class II-knockout mice, were able demonstrate M- ORF3a-specific cellular humoral immune responses. Hence, established MVA-T7pol represents efficient tool provides basis future development vaccines.

Язык: Английский

Процитировано

1